Panzem 2-methoxyestradiol: Phase II

In a U.S. double-blind Phase II trial in 33 hormone-refractory prostate cancer patients, 400 or 1600 mg oral Panzem once daily gave no serological or disease responses. Bioavailability was not signifi...